A patient with severe pain refractory to morphine is switched to methadone by an experienced pain physician. Incomplete cross-tolerance between opioids means the equianalgesic dose conversion ratio for methadone is not fixed and depends on the morphine equivalent daily dose (MEDD). This incomplete cross-tolerance is primarily attributed to:

• A Methadone's additional NMDA receptor antagonism at glutamate receptors involved in opioid tolerance and central sensitization ✓
• B Methadone being metabolized by a different CYP isoform (CYP2B6) than morphine, giving a pharmacokinetic tolerance reset
• C Methadone's very long and variable half-life (24–60 hours) causing unpredictable accumulation that mimics pharmacodynamic potency
• D Methadone having preferential affinity for delta opioid receptors not involved in morphine tolerance

Explanation

Opioid tolerance develops in part through central sensitization and NMDA receptor upregulation in the dorsal horn. Methadone uniquely possesses potent NMDA receptor antagonism (similar to ketamine), which counteracts the NMDA-mediated component of opioid tolerance. This means patients who have developed tolerance to morphine's mu-receptor effects encounter a relatively 'fresh' mechanism via methadone's NMDA blockade, making methadone more potent relative to predicted equianalgesic dose. Methadone also blocks serotonin and norepinephrine reuptake, contributing to multimodal analgesia. The variable half-life (24–60h) is a safety concern but is a pharmacokinetic, not pharmacodynamic, explanation for incomplete cross-tolerance.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.